Photo of Marco Campisi from researchgate.net
Jul 4, 2023, 16:50
Targeting CCR7-PI3Ky overcomes resistance to tyrosine kinase inhibitors AKL-rearranged lymphoma – Marco Campisi
I am happy to share that one of my collaborative efforts is finally out in Science Translational Medicine! A great work from the Chiarle lab at Università degli Studi di Torino and Boston Children’s Hospital.
Blockade of PI3Kγ and CCR7 signaling combined with ALK tyrosine kinase inhibitors treatment reduces primary resistance and survival of persister anaplastic large cell lymphoma.
Big thanks to all the authors, in particular to Claudia Voena and Roberto Chiarle who led this work!
For details: Click here
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45